Regeneron Pharmaceuticals, Inc.
REGN Healthcare Biotechnology
Regeneron Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, up 0.99% from fiscal 2024. In the quarter to June 2026, revenue grew 16.7%, EPS fell 4.68%, free cash flow fell 29.3% and total debt fell 26.6%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for three consecutive years.
Follow REGN
Regeneron Pharmaceuticals, Inc. (REGN) Operating margin
Regeneron Pharmaceuticals, Inc.'s operating margin over the twelve months to 30 June 2026 was 24.7%, down 0.2 percentage points from fiscal 2025 (25.0%). Over the past ten years it has ranged from 25.0% (fiscal 2025) to 55.7% (fiscal 2021) — the current reading is the lowest in ten years. That is above the Biotechnology industry median of 0.00% and above the Healthcare sector median of 0.00%.
Operating margin, annual
Embed this chart
Annual newest first
| Period | Operating margin | Change (points) |
|---|---|---|
| FY2025 | 25.0% | (3.15) |
| FY2024 | 28.1% | (2.75) |
| FY2023 | 30.9% | (8.08) |
| FY2022 | 38.9% | (16.74) |
| FY2021 | 55.7% | 13.58 |
| FY2020 | 42.1% | 8.39 |
| FY2019 | 33.7% | (15.55) |
| FY2018 | 49.3% | 13.84 |
| FY2017 | 35.4% | 8.03 |
| FY2016 | 27.4% | (3.13) |
Quarterly newest first
| Period | Operating margin | Change (points) |
|---|---|---|
| Jun 2026 | 30.2% | 12.32 |
| Mar 2026 | 17.8% | (4.82) |
| Dec 2025 | 22.7% | (4.70) |
| Sep 2025 | 27.4% | (2.02) |
| 42 more quarters | Free account |
Against its own ten years
Operating margin against peers
| Company | Operating margin |
|---|---|
| RPRX Royalty Pharma PLC compare | 59.6% |
| VRTX Vertex Pharmaceuticals Incorporated compare | 38.0% |
| ARGX argenex SE compare | 30.1% |
| REGN Regeneron Pharmaceuticals, Inc. | 24.7% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 20.8% |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 15.1% |
| RVMD Revolution Medicines, Inc. compare | 0.00% |
| MRNA Moderna, Inc. compare | −149.0% |
| ROIV Roivant Sciences Ltd. compare | −7,914.8% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Operating margin is
EBIT Margin tells an investor how much operating profit, before interest and taxes, a company keeps from each unit of revenue.
EBIT ÷ Revenue
More on REGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement